Biocytogen Responds to Harbour BioMed's Patent Claims: RenNano® is an Independently Developed Platform with Distinct Innovation and Full Legal Standing
Article content
BEIJING — In response to Harbour BioMed's recent press release regarding a procedural development in their ongoing legal claim, Biocytogen issues the following statement:
Article content
Biocytogen stands by its core values of independent innovation, respect for intellectual property, and a commitment to fair competition. The RenNano® platform is the result of independent, original R&D, based on Biocytogen's proprietary genome editing technologies. Its technical principles, design strategy, and IP scope are fundamentally different from the patents in dispute.
Article content
120 vs. 9 – A Significant Technical Divide of RenNano® Platform
Article content
;
Article content
Biocytogen Will Resolutely Take Legal Actions to Protect Its Rights
Article content
The RenNano® platform employs a large-fragment knock-in strategy that incorporates over 120 human V genes in situ, enabling a complete and functional human heavy chain antibody repertoire. In stark contrast, Harbour BioMed's HCAb platform introduces only 9 V genes through a small-fragment transgenic approach. This key difference reflects not only divergent technical strategies but also the depth, innovation, and translational potential of Biocytogen's antibody discovery platforms.
Article content
The decision referenced in Harbour BioMed's PR involves a procedural ruling on jurisdiction only and does not address the substance of the patent infringement case. Furthermore, the CNIPA's affirmation of patent validity is a routine administrative process that does not imply infringement. The underlying lawsuit has not yet entered the trial phase.
Article content
Biocytogen is currently evaluating all legal options and will resolutely defend its IP rights and scientific reputation. The RenNano® platform has been fully validated and is supported by a robust portfolio of domestic and international patents, clearly documenting its originality and independence.
Article content
We remain confident in:
Article content
The technical integrity and legal foundation of the RenNano® platform;
The non-infringement of any third-party IP;
Our continued leadership in antibody discovery and therapeutic innovation.
Article content
According to public records, the Chinese patent related to Harbour BioMed's HCAb platform is set to expire on July 22, 2025, further underscoring the short-sighted nature of any speculative claims. Regardless, Biocytogen will continue to uphold its rights, ensure business continuity, and deliver transformative technologies for global partners and patients.
Article content
Any misleading allegations or speculative narratives will not deter our team from advancing the RenMice® platform series with world-class innovation and delivering on our mission to accelerate therapeutic discovery.
Article content
Biocytogen's RenNano® Platform and Harbour BioMed's HCAb Platform
Article content
Biocytogen RenNano® Platform: Uses large-fragment knock-in technology to replace mouse genes with over 120 human V genes in situ, resulting in a full and functional human heavy chain variable region genomic repertoire.
Harbour BioMed HCAb Platform: Introduces only 9 V genes using small-fragment transgenic approaches.
Article content
About Biocytogen
Article content
Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® (RenMab™/ RenLite®/ RenNano®/ RenTCR-mimic™ ) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR-mimic antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of December 31, 2024, approximately 200 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and over 50 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit http://en.biocytogen.com.cn.
Article content
Article content
Article content
Contacts
Article content
Biocytogen Contacts
Article content
Article content
Antibody platform and assets:
Article content
BD-Licensing@biocytogen.com
Article content
Article content
Preclinical models and services:
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
3 hours ago
- Globe and Mail
The Stock Market Just Did Something for the Sixth Time Since 1957. History Says It Signals a Big Move in the S&P 500 in the Next Year.
Investors have experienced an exceptionally volatile market environment this year. The S&P 500 (SNPINDEX: ^GSPC) suffered its fifth-worst two-day decline in history after President Donald Trump announced his "Liberation Day" tariffs in early April, erasing $6.6 trillion in wealth. However, the benchmark index then staged one of its fastest comebacks after Trump paused the most severe tariffs for 90 days and moved to reduce the trade tensions with China that he'd previously ratcheted up. The S&P 500 rose by 6.2% in May, its best performance during that month since 1990. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » More impressive, the S&P 500 advanced 20.5% during the two-month period that ended on June 9. Since its inception in 1957, the index has only achieved a two-month return above 20% five times before. And in each of those cases, it delivered substantial additional gains in the next six months and the next year. History suggests the stock market will rocket higher in the next year The S&P 500 is considered the best barometer for the overall U.S. stock market due to its scope and diversity. The index measures the performance of 500 of the largest U.S. companies. Its components span all 11 market sectors and together account for about 80% of domestic equities by market value. The chart below shows the end dates for the five previous two-month periods when the S&P 500 gained 20% or more. It also shows how the index performed during the six-month and 12-month periods that followed them. S&P 500 Achieves 20%-Plus Return in 2 Months Forward 6-Month Return Forward 12-Month Return Feb. 6, 1975 10% 28% Oct. 6, 1982 20% 32% Dec. 7, 1998 11% 19% April 30, 2009 20% 36% May 18, 2020 21% 40% Average 16% 31% Data sources: YCharts, Carson Investment Research. In all five cases, the index kept rising. It gained an average of 16% in the next six months and 31% in the next year. On June 9, the S&P 500 closed at 6,006. If its performance from there matches the historical average: The index will advance by 16% from 6,006 to 6,967 by Dec. 9, 2025. That would be a 14% gain from its current level of 6,125. The index will advance 31% from 6,006 to 7,868 by June 9, 2026. That would be a 28% gain from its current level. Of course, the standard disclaimer applies here: Past performance is no guarantee of future results. But there is no harm in leaning into historical patterns so long as investors maintain a long-term mindset. Trump's tariffs could still derail the stock market again in the coming months The S&P 500 tumbled as much as 19% earlier this year when Trump started making radical changes to U.S. trade policy. The index has nearly recouped those losses and currently trades within a percentage point of its record high. But that does not mean tariffs will have no further impact on the stock market. The tariffs imposed to date have raised the average tax on U.S. imports to its highest level since 1941. Most economists think those duties will raise consumer prices and slow the country's economic growth. In fact, the pre-tariff consensus estimate was that U.S. gross domestic product (GDP) would increase by 2.3% this year, but the post-tariff consensus estimate is that it will increase by just 1.4%, according to Bloomberg. In early July, investors will get fresh monthly data on job openings, payrolls, unemployment, and inflation, and Trump's 90-day pause on his tariffs is due to expire on July 9. The market evidently has high expectations for the economic data considering the rebound the S&P 500 has already experienced, and Treasury Secretary Scott Bessent says Trump is likely to push back his self-imposed deadline to allow for trade negotiations to continue. However, if the economic data disappoints or Trump forges ahead with his draconian tariffs, the stock market could fall sharply. Investors need to keep that possibility in mind when they make decisions. Never buy a stock you are not prepared to hold through volatility. As Warren Buffett once advised, "You've got to be prepared when you buy a stock to have it go down 50%." Should you invest $1,000 in S&P 500 Index right now? Before you buy stock in S&P 500 Index, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and S&P 500 Index wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $704,676!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $950,198!* Now, it's worth noting Stock Advisor 's total average return is1,048% — a market-crushing outperformance compared to175%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 23, 2025
Globe and Mail
14 hours ago
- Globe and Mail
Lucintel Forecasts the Biomimetic Plastic Material Market in Japan Market to Reach $10.5 billion by 2031
"According to a market report by Lucintel, the future of the biomimetic plastic material market in Japan market looks promising with opportunities in the research institution, transportation, and consumer electronic markets. The biomimetic plastic material market in Japan market is expected to reach an estimated $10.5 billion by 2031, with a CAGR of 5.8% from 2025 to 2031" According to a market report by Lucintel, the future of the biomimetic plastic material market in Japan market looks promising with opportunities in the research institution, transportation, and consumer electronic markets. The biomimetic plastic material market in Japan market is expected to reach an estimated $10.5 billion by 2031, with a CAGR of 5.8% from 2025 to 2031 According to a market report by Lucintel, the future of the biomimetic plastic material market in Japan market looks promising with opportunities in the research institution, transportation, and consumer electronic markets. The biomimetic plastic material market in Japan market is expected to reach an estimated $10.5 billion by 2031, with a CAGR of 5.8% from 2025 to 2031. The major drivers for this market are the significantly growing automotive sector and rising demand from the electronics industry. A more than 150-page report to understand trends, opportunity and forecast in biomimetic plastic material market in Japan market to 2031 by type (biodegradable plastic, self-healing plastic, and others) and application (research institutions, transportation, consumer electronics, and others). Lucintel forecasts that, within the type category, biodegradable plastic is expected to witness higher growth over the forecast period due to growing environmental concerns. Within the application category, consumer electronics will remain the largest segment. Download sample by clicking on biomimetic plastic material market in Japan market This unique research report will enable you to make confident business decisions in this globally competitive marketplace. For a detailed table of contents, contact Lucintel at +1-972-636-5056 or write us at helpdesk@ To get access of more than 1000 reports at fraction of cost visit Lucintel's Analytics Dashboard. About Lucintel At Lucintel, we offer solutions for you growth through game changer ideas and robust market & unmet needs analysis. We are based in Dallas, TX and have been a trusted advisor for 1,000+ clients for over 20 years. We are quoted in several publications like the Wall Street Journal, ZACKS, and the Financial Times. Contact: Roy Almaguer Lucintel Dallas, Texas, USA Email: Tel. +1-972-636-5056 Explore Our Latest Publications Biomimetic Plastic Material Market in Australia Biomimetic Plastic Material Market in Brazil Biomimetic Plastic Material Market in Netherlands Biomimetic Plastic Material Market in South Africa Biomimetic Plastic Material Market in United States Media Contact Company Name: Lucintel Contact Person: Roy Almaguer Email: Send Email Phone: 972.636.5056 Address: 8951 Cypress Waters Blvd., Suite 160 City: Dallas State: TEXAS Country: United States Website:
The Market Online
15 hours ago
- The Market Online
@ the Bell: Truce, data, and deals drive market moves
Canada's main stock index took a stumble on Friday, following a record high reached earlier in the session. Markets in both Canada and the US were lifted by the continued stability of a ceasefire between Israel and Iran, along with a series of economic reports that strengthened expectations for potential interest rate cuts by the Federal Reserve later this year. Meanwhile, US stocks moved upward to end the week, indicating a possible continuation of recent market momentum. Investor optimism was further supported by the anticipated release of the Fed's preferred inflation measure and news of a US-China agreement aimed at accelerating the delivery of rare earth materials vital to numerous industries. The Canadian dollar traded for 72.83 cents US compared to 72.86 cents US on Thursday. US crude futures traded $0.30 higher at US$65.54 a barrel, and the Brent contract rose $0.20 to US$67.93 a barrel. The price of gold was down US$13.18 to US$3,382.33. In world markets, the Nikkei was up 566.21 points to ¥40,150.79, the Hang Seng was down 41.25 points to HK$24,284.15, the FTSE was up 63.31 points to ₤8,798.91, and the DAX was up 383.92 points to €24,033.22. The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.
